Ranbaxy's Canada arm in licensing arrangement with Janssen-Ortho

New Delhi, Oct 6 (UNI) Ranbaxy Laboratories Ltd today announced that its wholly-owned subsidiary, Ranbaxy Pharmaceuticals Canada (RPCI), has entered into an licensing and supply agreement with Janssen-Ortho Inc (JOI), for a generic fentanyl patch, sold under Ranbaxy's label, RAN-Fentanyl Transdermal System.

This is the second product to be commercialised by RPCI as part of a licensing arrangement between the companies.

''This agreement, which also includes Risperidone, will provide Ranbaxy with an opportunity to commercialise products that continue to have a favourable impact on patient care, as well as on the Canadian healthcare system, and allow Ranbaxy to reinforce its presence in Canada,'' RPCI President and General Manager Bill Abboud said.

RAN-Fentanyl Transdermal System is a trademark of the company.

The system is classified as an opioid analgesic drug indicated for the management of persistent, moderate to severe chronic pain and is supplied in a patch form.

The potential market for a generic fentanyl patch is expected to reach 50 million Canadian dollar. It will be available through pharmacies and wholesalers immediately.

UNI CS RA DS1406